Seeking Alpha

Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control

ATLANTA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (FEMY) (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and ...
AOL

Number of Women Seeking Permanent Birth Control Increased 50% After Abortion Overturn

The number of women who sought permanent birth control via surgery increased in the wake of Roe v. Wade's overturn in 2022 Researchers saw a 51% increase in tubal ligation in four states “There was a ...
Nasdaq

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of ...
KRQE Blogs

Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control

ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, ...
Nasdaq

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

--$12 million senior secured convertible notes for total potential proceeds of $58 million, if all warrants are exercised for cash, reflecting strong investor confidence in Femasys’ women’s health ...
The American Journal of Managed Care

5 Birth Control Methods That Are Safe for Women to Use

Education on birth control and its potential adverse effects is vital to women choosing the type that best suits them. Skepticism surrounding hormonal birth control has been increasing nationwide, ...
Seeking Alpha

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

ATLANTA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (FEMY) (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and ...